Glycopyrrolate/formoterol fumarate vs Olodaterol/tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere

Marketed by AstraZeneca

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Weak signal

NCT03324607 · Phase 2/3 · completed

The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.

Reported efficacy

Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)

Result source: NCT03324607

Olodaterol/tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrrolate/​formoterol fumarateOlodaterol/​tiotropium bromide
Moderate or severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
SGRQ total, change—Not reported—Not reported
TDI focal score—Not reported—Not reported

Moderate or severe exacerbations, annualised rate

Glycopyrrolate/​formoterol fumarate
—Not reported
Olodaterol/​tiotropium bromide
—Not reported

Trough FEV1, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Olodaterol/​tiotropium bromide
—Not reported

SGRQ total, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Olodaterol/​tiotropium bromide
—Not reported

TDI focal score

Glycopyrrolate/​formoterol fumarate
—Not reported
Olodaterol/​tiotropium bromide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Olodaterol/tiotropium bromide: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Glycopyrrolate/formoterol fumarate: 2 of 4 rows · Olodaterol/tiotropium bromide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrrolate/​formoterol fumarate
Dropout rate
0%a
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Serious AEs
0%a
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
12.5%
NCT03081156 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrrolate/formoterol fumarate

FVC 0.342 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 342 mL as posted
FEV1 0.219 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 219 mL as posted
Six Minute Walk 16.2 m @ 2wk
absolute change · m
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
SGRQ Total -1.2 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
RPD -0.75 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
Exercise Endurance Time Seconds 382.5 vs 328 placebo seconds
absolute value · seconds
NCT03081156 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Olodaterol/tiotropium bromide's landscape